Top Markets
Coin of the day
Heat Biologics, Inc. Heat Biologics, Inc.

Heat Biologics, Inc.

HTBX
주식 순위 #24400
Heat Biologics, Inc. is an integrated biopharmaceutical company focused on... Heat Biologics, Inc. is an integrated biopharmaceutical company focused on creating immune-modulating therapies and vaccines. The firm's primary goal is to harness the immune system to fight a variety of illnesses, including both cancerous growths and infectious diseases. A cornerstone of their approach is the gp96 platform, which comprises two key components: ImPACT, an allogenic cell-based system designed to stimulate and proliferate T-cells as an immune activator, and ComPACT, a singular product engineered to achieve both antigen-driven T-cell activation and specific co-stimulation simultaneously. Their development pipeline includes several clinical-stage assets. HS-110 has finished enrolling patients for its Phase II trial targeting advanced non-small cell lung cancer, while HS-130 is currently in a Phase I clinical trial for advanced solid tumors. Furthermore, PTX-35, a novel T-cell co-stimulator agonist antibody that acts on DR3/TNFRSF25, is being evaluated in a Phase I clinical trial for diverse immunotherapy applications. The company is also advancing a COVID-19 vaccine, which is currently in the preclinical stage. Heat Biologics, Inc. has partnered with Dr. James Shapiro at the University of Alberta to develop a surrogate mouse version of PTX-35. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
주가
$2.38
마지막 동기화: 2022-05-03
시가총액
$61.07M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Heat Biologics, Inc. (HTBX)

카테고리

Heat Biologics, Inc. (HTBX)의 발행 주식 수
August 2026 기준 발행 주식 수: 0
Heat Biologics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 0입니다. August 2026 말 기준 회사는 0주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Heat Biologics, Inc. (HTBX)의 발행 주식 수 기록 (2026 ~ 2026)
매년 말 기준 발행 주식 수
연도 발행 주식 수 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 발행 주식 수
회사 발행 주식 수 차이 국가
253.90M -
US
62.19M -
NL
396.00M -
US
483.58M -
AU
- -
CH